Skip to main content
. 2018 May 15;8:7601. doi: 10.1038/s41598-018-25856-0

Figure 1.

Figure 1

The AAV-mediated induction of IL-10 improves CAWS-induced cardiac dysfunction (A) Mice were injected intramuscularly with AAV-GFP (control) or AAV-IL-10. The plasma IL-10 levels were assessed at 2 and 4 weeks after the injection of AAV (n = 11–13). ND indicates not detected. (B–F) Mice were treated intraperitoneally with CAWS or vehicle at 2 weeks after the AAV injection. The survival of CAWS-treated AAV-GFP and AAV-IL-10 mice was analyzed using Kaplan-Meier method (n = 10–12) (B). Echocardiography was performed at 28 and 56 days after CAWS or vehicle treatment. Two-dimensional M-mode echocardiograms at 56 days are shown (C). The cardiac function %FS, (D) and dimension LVEDD, (E), and the heart weight/body weight ratio (F) were assessed at 28 and 56 days after CAWS or vehicle treatment (%FS, n = 7–17 [day 28]; n = 4–7 [day 56], LVEDD, n = 7–17 [day 28]; n = 3–6 [day 56], the heart weight/body weight ratio (n = 10–14 [day 28]; n = 5–9 [day 56]). Data are expressed as the mean ± SEM. *p < 0.05, **p < 0.01.